Area of research
Genetics · Immunology
Research interest
Research interests include Chronic Lymphocytic Leukemia Research, Immunodeficiency and Autoimmune Disorders, Lymphoma Diagnosis and Treatment, and Acute Lymphoblastic Leukemia research.
The mutational landscape and functional effects of noncoding ultraconserved elements in human cancers
Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome
Molecular map of chronic lymphocytic leukemia and its impact on outcome
cyCombine allows for robust integration of single-cell cytometry datasets within and across technologies
Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatment
Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History
<i>miR-29</i> modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors
A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation
Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia
Growth dynamics in naturally progressing chronic lymphocytic leukaemia
A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion
Dysregulation of different classes of tRNA fragments in chronic lymphocytic leukemia
Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia
Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia
Genetic dynamics in untreated CLL patients with either stable or progressive disease: a longitudinal study
Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia
Recurrent Mutations in EGR2 Direct Specific Epigenetic Reconfiguration in Chronic Lymphocytic Leukemia
<i>MicroRNA</i> dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia
DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
Dysregulation of a family of short noncoding RNAs, tsRNAs, in human cancer
Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia
High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia
Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib
The Dohner fluorescence <i>in situ</i> hybridization prognostic classification of chronic lymphocytic leukaemia (<scp>CLL</scp>): the <scp>CLL</scp> Research Consortium experience
EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia
A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study
Transcriptome Sequencing Reveals Potential Mechanism of Cryptic 3’ Splice Site Selection in SF3B1-mutated Cancers
Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B
<i>TCL1</i> targeting <i>miR-3676</i> is codeleted with tumor protein p53 in chronic lymphocytic leukemia